| Literature DB >> 15655579 |
Judit Jánosi1, Anna Sebestyén, József Bocsi, Gábor Barna, Katalin Nagy, István Vályi-Nagy, László Kopper.
Abstract
Statins have been used successfully in the treatment of hypercholesteremia. Moreover, in vitro studies have shown that statins can trigger apoptosis in a variety of tumor cell lines. In the present study we analysed the effect of mevastatin -- a novel inhibitor of HMG-COA reductase, the rate-limiting enzyme of the mevalonate pathway -- on U266 human myeloma cells. Apoptosis induced by mevastatin was associated with increased caspase activity and depolarisation of mitochondrial membrane. Expression of BCL-2 mRNA and protein was down-regulated, with no change in BAX or BCLxL protein production. The mitochondrial program was supported by caspase-8 and cleaved BID activity. None of the antibodies neutralising death-ligand/death-receptor pathway -- TRAIL-R2Fc, anti-TNF-a, anti FASL (NOK-1) -- influenced the mevastatin-induced apoptosis. Mevastatin also stimulated shedding of syndecan-1 from the surface of myeloma cells.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15655579 DOI: HUON.2004.48.4.0333
Source DB: PubMed Journal: Magy Onkol ISSN: 0025-0244